Global Perspective on Lung Cancer in 2019 and Beyond
Expert perspectives and strategic insights on the latest therapeutic developments and translational research in lung cancer treatment. Topics include: clinical decision making, to what extent will emerging data affect ongoing research, development of new compounds, and future treatment paradigms.
Faculty Chair
Corey Langer, MD, FACP
University of Pennsylvania, US
Look Inside This Report
Download a sample of this report and start discovering the insights
Key Takeaways and Strategic Insights
The report includes recommendations and key takeaways on
- Immunotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Immunotherapy in Potentially Curable (Stage I-III) NSCLC
- Evolving Standards in Small Cell Lung Cancer (SCLC)
- Extending Outcomes in EGFR-Mutated NSCLC
- Targeting ALK and Other Oncogenic Drivers
Faculty Members
Benjamin Besse, MD, PhD
Gustave Roussy
Jamie Chaft, MD
Memorial Sloan Kettering Cancer Center
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital
Roy Herbst, MD, PhD
Yale Cancer Center
Keith M. Kerr, FRCPath
Aberdeen University Medical School
Solange Peters, MD, PhD
Lausanne University Hospital
Ignacio I. Wistuba, MD
MD Anderson Cancer Center
Antoinette Wozniak, MD
University of Pittsburgh Medical Center
